Greenwich Lifesciences, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Greenwich LifeSciences, Inc. announced the successful election of all five director nominees and the ratification of MaloneBailey LLP as its independent auditor at its Annual Meeting of Stockholders.
NASDAQ
Greenwich LifeSciences, Inc. has dismissed RBSM LLP and engaged MaloneBailey LLP as its new independent registered public accounting firm, following disclosures of material weaknesses in internal controls over financial reporting.
NASDAQ
Greenwich LifeSciences successfully held its annual meeting, electing all director nominees and approving the appointment of its accounting firm and an increase in shares for its equity incentive plan.
NASDAQ
Greenwich LifeSciences has entered into a securities purchase agreement with its CEO, Snehal Patel, for a private placement of 174,825 shares at $14.30 per share, raising approximately $2.5 million.
NASDAQ
Greenwich LifeSciences has dismissed MaloneBailey LLP and appointed RBSM LLP as its new independent registered public accounting firm, effective February 15, 2024.
NASDAQ
Greenwich LifeSciences has provided an update on its Phase III clinical trial, Flamingo-01, for its breast cancer immunotherapy, GLSI-100, including expansion of the trial to include more patients and sites.